Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral piclidenoson in moderate-to-severe plaque psoriasis
2017-000214-27Phase 3Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of piclidenoson in plaque psoriasis (4 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoint: Proportion of subjects achieving PASI 75. Started Aug 2018; status: completed.
02
Drugs
piclidenoson
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2017-000214-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000214-27.